5460-79-7

Basic information

• Product Name: 1-METHYL-4-CYANO-4-(3-METHOXYPHENYL)-PIPERIDINE
• Synonyms: 1-METHYL-4-CYANO-4-(3-METHOXYPHENYL)-PIPERIDINE;4-CYANO-4-(3-METHOXYPHENYL)-1-METHYLPIPERIDINE;4-(3-methoxyphenyl)-1-methylpiperidine-4-carbonitrile;4-(3-Methoxyphenyl)-1-methyl-4-piperidinecarbonitrile;4-(3-methoxyphenyl)-1-methyl-isonipecotonitrile;4-(M-Methoxyphenyl)-1-Methylisonipecotonitrile;4-Cyano-4-M-Methoxyphenyl-1-Methylpiperidine;NSC 21330
• CAS NO: 5460-79-7
• Molecular Formula: C₁₄H₁₈N₂O
• Molecular Weight: 230.31
• EINECS: 226-742-7
• Product Categories: Pyrans, Piperidines & Piperazines;Aromatics;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 5460-79-7.mol
• Article Data: 5

Chemical Properties

• Melting Point: 43-47°C
• Boiling Point: 377.2°Cat760mmHg
• Flash Point: 181.9°C
• Appearance: /
• Density: 1.1g/cm³
• Vapor Pressure: 6.87E-06mmHg at 25°C
• Refractive Index: 1.556
• PKA: 6.56±0.10(Predicted)
• CAS DataBase Reference: 1-METHYL-4-CYANO-4-(3-METHOXYPHENYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-METHYL-4-CYANO-4-(3-METHOXYPHENYL)-PIPERIDINE(5460-79-7)
• EPA Substance Registry System: 1-METHYL-4-CYANO-4-(3-METHOXYPHENYL)-PIPERIDINE(5460-79-7)

Safety Data

• RIDADR: UN3439
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 5460-79-7(Hazardous Substances Data)

Usage

Uses

4-Cyano-4-(3-methoxyphenyl)-1-methylpiperidine is an aryl piperidine derivative used in the preparation of 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents.

Synthesis Reference(s)

Journal of Heterocyclic Chemistry, 23, p. 73, 1986 DOI: 10.1002/jhet.5570230115

InChI:InChI=1/C14H18N2O/c1-16-8-6-14(11-15,7-9-16)12-4-3-5-13(10-12)17-2/h3-5,10H,6-9H2,1-2H3

Upstream product

• 19924-43-7 3-methoxyphenylacetonitrile 
• 51-75-2 nitrogen mustard 
• 55-86-7 mechlorethamine hydrochloride 
• 105-59-9 N-Methyldiethanolamine 
• 37786-58-6 3-cyano-1-(dimethylamino)-3-(m-methoxyphenyl)propane 
• 620593-93-3 4-hydroxy-2-(2-hydroxyethyl)-2-(3-methoxyphenyl)butanenitrile 
• 74-89-5 methylamine 

Downstream Products

• 43152-59-6 1-[4-(3-methoxy-phenyl)-1-methyl-piperidin-4-yl]-propan-1-one 
• 64417-39-6 1-[4-(3-methoxy-phenyl)-1-methyl-[4]piperidyl]-ethanone 
• 857373-32-1 C-[4-(3-methoxy-phenyl)-1-methyl-[4]piperidyl]-methylamine 
• 106275-10-9 4-(3-hydroxy-phenyl)-1-methyl-piperidine-4-carboxylic acid 
• 874532-98-6 4-(3-methoxy-phenyl)-1-methyl-piperidine-4-carboxylic acid 
• 73737-18-5 ketobemidone hydrobromide 
• 64058-44-2 1-[4-(3-hydroxy-phenyl)-1-methyl-[4]piperidyl]-ethanone 
• 469-79-4 ketobemidone 
• 66924-19-4 1-[4-(3-hydroxy-phenyl)-1-methyl-[4]piperidyl]-butan-1-one 
• 63080-01-3 4-(3-methoxy-phenyl)-1-methyl-piperidine-4-carboxylic acid ethyl ester 
• 857946-13-5 N-[4-(3-methoxy-phenyl)-1-methyl-[4]piperidylmethyl]-acetamide 
• 468-56-4 Bemidone 
• 1043886-45-8 C₁₃H₁₆N₂O 
• 79025-11-9 1-[4-(3-methoxy-phenyl)-1-methyl-[4]piperidyl]-propan-1-one; hydrochloride 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF SEVERE PAIN

The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for the treatment of severe pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of postoperative pain, cancer pain, kidney stones pain, fractures, local pain, chronic pain, chemotherapy induced pain, neuropathic pain, post herpetic neuralgia, neuralgia, motor neurone disease, diabetic neuropathy, postherpetic neuralgia, injury, post-operative pain, osteoarthritis, rheumatoid arthritis, multiple sclerosis, spinal cord injury, migraine, HIV related neuropathic pain, cancer pain and lower back pain.

Novel 1,4-diarylpiperidine-4-methylureas as anti-hyperlipidemic agents: Dual effectors on acyl-CoA:cholesterol O-acyltransferase and low-density lipoprotein receptor expression

A family of 1,4-diarylpiperidine-4-methylureas were designed and synthesized as novel dual effectors on ACAT and LDL receptor expression. We examined SAR of the synthesized compounds focusing on substitution at the three aromatic parts of the starting compound 1 and succeeded in identifying essential substituents for inhibition of ACAT and up-regulation of hepatic LDL receptor expression. Especially, we found that compound 12f, which can easily be prepared, has biological properties comparable to those of SMP-797, a promising ACAT inhibitor. In addition, the in vitro effects of 12f on lipid metabolism were substantially superior to those of a known ACAT inhibitor, Avasimibe.

Synthesis of ketobemidone precursors via phase-transfer catalysis

-